Sort
48,018 grants matching “immunotherapy”
Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core
$380,670Gatien Moriceau · University Of California Los Angeles · P01 · FY2023 · CA
Novel Combinations of Radiation and Immunotherapy
$380,668Jennifer Jones · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Finding emergent structure in multi-sample biological data with the dual geometry of cells and features
$380,650Matthew John Hirn · Michigan State University · R01 · FY2019 · GM
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY
$380,640Wayne William Hancock · Children'S Hosp Of Philadelphia · R01 · FY2016 · CA
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY
$380,640Wayne William Hancock · Children'S Hosp Of Philadelphia · R01 · FY2018 · CA
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY
$380,640Wayne William Hancock · Children'S Hosp Of Philadelphia · R01 · FY2017 · CA
eDyNAmiC-TEXASSW
$380,633Zhijian J Chen · Ut Southwestern Medical Center · OT2 · FY2023 · CA
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
$380,627Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2021 · CA
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow
$380,582Geoffrey Roger Hill · Fred Hutchinson Cancer Research Center · P01 · FY2021 · CA
CANCER AND LEUKEMIA GROUP B
$380,576University Of Chicago · U10 · FY2002 · CA
Anti-ceramide immunotherapy for diabetic retinopathy
$380,566Julia V Busik · Michigan State University · R01 · FY2021 · EY
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
$380,517Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2020 · CA
Mechanisms of liver metastasis and associated resistance to immunotherapy
$380,509Benjamin Izar · Columbia University Health Sciences · R37 · FY2021 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
$380,473David P Carbone · Ohio State University · R01 · FY2023 · CA
Chemical proteomic investigation of lipid kinase specificity and druggability
$380,466Ku-Lung Hsu · University Of Texas At Austin · R01 · FY2024 · AI
Arming Neutrophils for the Destruction of HIV by Anti-HIV Antibody
$380,454Lisa A. Cavacini · Beth Israel Deaconess Medical Center · R01 · FY2010 · AI
Role of microbial-modulated bile acid receptor signaling in breast cancer
$380,449Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA
Four-dimensional Adhesion Frequency Assay for Full Profiling of Receptor-ligand Interactions on Cells
$380,353Yuebing Zheng · University Of Texas At Austin · R01 · FY2024 · GM
Four-dimensional Adhesion Frequency Assay for Full Profiling of Receptor-ligand Interactions on Cells
$380,352Yuebing Zheng · University Of Texas At Austin · R01 · FY2025 · GM
Sequence optimization for mRNA cancer therapy
$380,337Georg Seelig · University Of Washington · R33 · FY2025 · CA
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE
$380,335Pier Paolo Pandolfi · Sloan-Kettering Inst Can Research · P50 · FY2008 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$380,325Ann Richmond · Vanderbilt University · R01 · FY2023 · CA
Biochemistry of Apoptosis in CLL
$380,292John C Reed · University Of California, San Diego · P01 · FY2009 · CA
Silencing of HIV-1 proviruses by epigenetically targeting transcriptional elongation
$380,273Qin Feng · University Of Houston · R33 · FY2021 · AI
Targeting the Immunosuppressive Tumor Microenvironment for Colorectal Cancer Treatment
$380,262Qingding Wang · University Of Kentucky · R01 · FY2024 · CA